Amid industry’s cell therapy automation push, Cellares and Ori dominate the field: report

With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies have emerged in recent years on a mission to simplify production for the | With interest in automated cell therapy production beginning to build from about 2016 onward, some 23 companies working in the field have now raised a collective $1.1 billion across 34 rounds through April 24, data intelligence platform Tracxn said in a new report.